SCM
LXEO icon

Superstring Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Superstring Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52,616
Closed -$346K – 44
2024
Q4 		$346K Buy
+52,616
New +$414K 0.3% 37

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Superstring Capital Management's LXEO Position: Q1 2025 in Review

Superstring Capital Management sold out of Lexeo Therapeutics (LXEO) in Q1 2025, closing a stake of 52,616 shares — an estimated $346K sold.

Superstring Capital Management first reported a position in LXEO in Q4 2024 and held it in 1 quarter. The position peaked at $346K in Q4 2024. 88 funds tracked by Wall St. Rank hold LXEO as of Q1 2025.

  • Superstring Capital Management reported no remaining Lexeo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Superstring Capital Management sold 52,616 Lexeo Therapeutics shares in Q1 2025, an estimated $346K.
  • Superstring Capital Management first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 1 quarter.
  • Superstring Capital Management's Lexeo Therapeutics position peaked at $346K in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2025.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.